You are here


Member Since 2006

W. Richard Staub III

President, Research & Development Solutions

Richard Staub is president of the Research & Development Solutions global business unit at IQVIA, leading the world’s largest contract research organization (CRO). Supported by high-powered information and technology assets, the clinical experts in Research & Development Solutions leverage comprehensive, evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution. Richard also serves as chair of the Research & Development Solutions Executive Committee.

Previously, he led Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013. Richard joined Novella in 2004 and served as both president and CEO. Under his leadership, Novella became a distinctively agile, results-oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology. Prior to Novella, he was senior vice president of global business development for one of the world’s largest CROs. Richard’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.

Richard has a bachelor’s degree in Economics from the University of North Carolina at Chapel Hill.

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2007

Gold Standard  Task Force Participation

Gold Standard Subcommittee Chair, Accreditation Review Board Member & Member: Ann Skye, BSN, MPH, Associate Director, Employee Health Management

Global Gold Standard  Task Force Participation

Global Gold Standard Subcommittee Chair and Member: Ann Skye, BSN, MPH, Associate Director, Employee Health Management

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Jeffrey A. Spaeder, MD, Chief Medical & Scientific Officer; Alan Metz, MD, Senior Vice President and Managing Director, Strategic Partnerships


IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit